Advertisement
ACET vs EVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and EVO is a Buy.
ACET's RSI Indicator stays in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in 239 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ACET may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ACET moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACET crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACET entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.279) is normal, around the industry mean (3.070). P/E Ratio (-0.344) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EVO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 37 cases where EVO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EVO's RSI Indicator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on EVO as a result. In 73 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 186 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (8.542). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (-1.854). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ACET | EVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 93 | 65 | |
P/E GROWTH RATING 1..100 | 8 | 1 | |
SEASONALITY SCORE 1..100 | n/a | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACET's Valuation (47) in the Medical Distributors industry is somewhat better than the same rating for EVO (92) in the null industry. This means that ACET’s stock grew somewhat faster than EVO’s over the last 12 months.
ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as EVO (100) in the null industry. This means that ACET’s stock grew similarly to EVO’s over the last 12 months.
EVO's SMR Rating (96) in the null industry is in the same range as ACET (98) in the Medical Distributors industry. This means that EVO’s stock grew similarly to ACET’s over the last 12 months.
EVO's Price Growth Rating (65) in the null industry is in the same range as ACET (93) in the Medical Distributors industry. This means that EVO’s stock grew similarly to ACET’s over the last 12 months.
EVO's P/E Growth Rating (1) in the null industry is in the same range as ACET (8) in the Medical Distributors industry. This means that EVO’s stock grew similarly to ACET’s over the last 12 months.
| ACET | EVO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 79% |
| Stochastic ODDS (%) | 3 days ago 86% | 2 days ago 81% |
| Momentum ODDS (%) | N/A | 2 days ago 72% |
| MACD ODDS (%) | N/A | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Advances ODDS (%) | about 1 month ago 84% | 3 days ago 68% |
| Declines ODDS (%) | 4 days ago 88% | 8 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 87% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while EVO’s FA Score has 1 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- EVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 4 TA indicator(s) are bullish while EVO’s TA Score has 5 bullish TA indicator(s).
- ACET’s TA Score: 4 bullish, 5 bearish.
- EVO’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACET (@Biotechnology) experienced а -16.36% price change this week, while EVO (@Pharmaceuticals: Generic) price change was +2.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.39%. For the same industry, the average monthly price growth was -11.11%, and the average quarterly price growth was -14.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.06%. For the same industry, the average monthly price growth was -9.37%, and the average quarterly price growth was +2.92%.
Reported Earning Dates
ACET is expected to report earnings on Nov 04, 2026.
EVO is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+5.39% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-0.06% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ACET and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACET has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ACET | 1D Price Change % | ||
|---|---|---|---|---|
| ACET | 100% | -6.04% | ||
| VIR - ACET | 44% Loosely correlated | -1.51% | ||
| OGI - ACET | 41% Loosely correlated | +0.54% | ||
| RXRX - ACET | 40% Loosely correlated | -2.53% | ||
| ABEO - ACET | 38% Loosely correlated | +0.22% | ||
| IMTX - ACET | 37% Loosely correlated | -0.54% | ||
More | ||||